Finance
FDA fast-tracks psychedelic drug research following Trump executive order
It's a big shift toward supporting psychedelic-based medicines for treatment-resistant depression, PTSD and substance use disorders, the FDA said.
C
CNBC
April 24, 2026· 1 min read
GM
FinanceIt's a big shift toward supporting psychedelic-based medicines for treatment-resistant depression, PTSD and substance use disorders, the FDA said.
Original article
FDA fast-tracks psychedelic drug research following Trump executive order
Published by CNBC